The L16HTHOUSE Study

L16HTHOUSE is a research trial testing an experimental medication for treating speech, motor, learning, and other developmental delays in children and adolescents with 16p11.2 deletion syndrome.

The L16HTHOUSE Study is now underway to evaluate the safety, tolerability, and effectiveness of a new medication, monitoring the results in helping with the developmental impairments in children and adolescents with the 16p11.2 deletion.

Redenlab is partnering with the Simon’s Foundation for this important trial in children and adolescents with the 16p11.2 deletion across sites in Eastern, Western and Southern USA.

To find out more about the study, click here.

Tags: , , , , , ,

Related Post

Examination of speech processing in noise reveals cognitive deficits in early Huntington’s disease 

  • Posted on 7 October, 2025
    Struggling to follow a conversation in noise could be more than just annoying, it might signal early cognitive issues in...
    Read more

    Phase 2a/b randomised placebo-controlled dose-escalation trial of triheptanoin for ataxia-telangiectasia

    • Posted on 25 July, 2025
      A new clinical trial has found early evidence that a metabolic therapy could improve outcomes for people with ataxia-telangiectasia (A-T),...
      Read more

      Rapid repetitive syllable sounds associate with episodic memory, executive function, and working memory in cognitively healthy and subjectively impaired older adults

      • Posted on 21 July, 2025
        Could a 10-second speech test repeating “pa,” “ta,” “ka” be the key to earlier detection of Alzheimer’s risk? Our new...
        Read more